RBC Capital keeps Biogen at Outperform and lifts price target to $272
RBC Capital maintained Biogen at Outperform and raised its target from $256 to $272. Source: TradingView, with reference data from Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RBC Capital maintained its Outperform rating on Biogen and raised its price target from $256 to $272, a 6.2% increase. According to the source, the new target implies roughly 11.5% upside from the October 28 close of $244.05. The information was published by TradingView, with data supplied by Benzinga.
RBC Capital also kept Bausch & Lomb at Outperform and lifted its target from $21 to $23, a 9.5% rise. That target implies about 12.7% upside from the October 28 close of $20.40.
For Biogen, price targets in the five most recent analyst notes over the past 30 days ranged from $225 to $300, spanning Wedbush at Neutral to UBS at Buy.
why it matters
Rating and target revisions like these are routine and usually reflect analysts' current views. They rarely move the broader market unless they come with new revenue or earnings data from the companies.
tags
instruments
sources
- RBC Capital maintains Biogen at Outperform, raises price target to $272 from $256 — TradingView, 29 October 2026 at 19:19 UTC
- RBC Capital maintains Bausch & Lomb at Outperform, raises price target to $23 from $21 — TradingView, 29 October 2026 at 19:15 UTC
- RBC Capital maintains GE HealthCare Techs at Outperform, raises price target to $90 from $80 — TradingView, 29 October 2026 at 19:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗